about
M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitisGuidelines for the treatment of antiphospholipid syndrome.High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statinsHMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis.L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis?Diagnostic and classification criteria of Takayasu arteritis.Central nervous system vasculitis in adults: An update.Leflunomide in Takayasu arteritis - A long term observational study.Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis.Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet's diseaseAnti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases.Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome.CD4+ T helper cells and regulatory T cells in active lupus nephritis: an imbalance towards a predominant Th1 response?Clinical interventions for Takayasu arteritis: A systematic review.Retinal angiography and colour Doppler of retrobulbar vessels in Takayasu arteritis.Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?Homocysteine levels in Takayasu arteritis -- a risk factor for arterial ischemic events.Atypical manifestations in Brazilian patients with neuro-Behçet's disease.Behçet disease: clinical features and management in a Brazilian tertiary hospital.Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques.Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patientsShort-term effect of leflunomide in patients with Takayasu arteritis: an observational studyAntiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritisHigh mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestationsCryopyrin associated periodic syndrome with neurological involvement in a 50-year-old patientNeurologic manifestations of antiphospholipid syndromeCutaneous Vasculitis in a Patient with Crohn's Disease Treated with AdalimumabA retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?Translation and validation of the Indian Takayasu clinical activity score (ITAS2010) for the Brazilian Portuguese languageEndothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis(18)F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu's arteritis
P50
Q33706866-C9E541D0-C653-437C-AACA-92273C30C61FQ34821893-128CD9DD-0CBA-48C5-90EF-BCCA3E35F062Q35782029-6D208A40-3933-4B55-BC3D-A8A0C9424B6BQ38001886-DCB686E8-17B4-443F-B3D2-619AEB339FCBQ38088034-A0CD36EF-33BA-471F-A847-4E1D6FA4FAADQ38181669-0F74F8FB-C3B9-4FB8-9B59-68274EB0A9D5Q39021305-72F3DB72-DE9E-447F-BAA4-4E894946C03CQ39961951-80A1794F-E594-4B06-B680-9AD78CAFC6E4Q40590983-3D50AF3A-A02C-46B7-AAFC-22C1944664B9Q42660016-14894F68-2E26-48F3-8FED-3EC7C7E1BC84Q43920314-9D1A26B7-4E84-4BA9-B4A0-4CF5434CF2ADQ46982104-FBDE2D43-F81B-4834-A022-56F63A4466A7Q47748317-B671EA91-216D-436C-846E-1540FAEF2667Q47998169-6410B988-150F-480C-82CF-A9536C4B5A7AQ50461640-74B9F5CC-8FAA-4C0C-97D8-8F15F13BEA1DQ50791154-153FFF44-0D26-4F2A-A235-A21816C91E66Q51347603-BEC52278-7AAA-43C5-AA2B-D9971ACDFEC6Q51375478-16F7F81E-7E20-4180-9372-BBCE0A8B4E32Q51387835-49B2525B-6B5C-4A36-81B3-A785F23E8DD8Q54595226-B09B9F54-2AFB-4983-8A00-04E3541EE94FQ82844650-21366F26-B1A9-4733-8A33-3F486804901FQ83605742-0D2B49EC-11D0-4FDC-B3F2-D4C1E1EA9380Q84218398-DA49CC07-60A5-4080-ABC0-D1DD9B7255F7Q85584842-B2B89DCA-DD57-4EAF-B183-399031C17A8BQ87273102-E796A7F3-498C-4B64-9FEF-F30AA386F4F8Q88696090-422FD417-025E-4D56-864B-2CD29FE89369Q88852090-2B31F534-5054-4F3F-87C2-E04975B6477BQ90569779-CCD21219-D838-4F24-A433-49DDB5697D58Q90751850-F85012CF-9DF5-43E0-9B50-A7795CB4E27EQ91106822-52B83EAB-051A-48DD-A32C-B3130D7BC5D0Q95486600-57AE3010-AA3F-4D67-A562-6087D4C3D9F6
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Alexandre Wagner Silva Souza
@ast
Alexandre Wagner Silva Souza
@en
Alexandre Wagner Silva Souza
@es
Alexandre Wagner Silva Souza
@nl
type
label
Alexandre Wagner Silva Souza
@ast
Alexandre Wagner Silva Souza
@en
Alexandre Wagner Silva Souza
@es
Alexandre Wagner Silva Souza
@nl
prefLabel
Alexandre Wagner Silva Souza
@ast
Alexandre Wagner Silva Souza
@en
Alexandre Wagner Silva Souza
@es
Alexandre Wagner Silva Souza
@nl
P1153
9243496300
P31
P496
0000-0001-7681-6215